Special Issue

Therapy for Gliomas

Message from the Guest Editors

Gliomas represent frequent and aggressive malignant primary brain tumors in adults and pediatric patients. Despite growing knowledge of the molecular changes responsible for tumor development, these tumors remain neoplastic with unmet medical needs. So, it is very important to characterize gliomas with advanced imaging such as MR spectroscopy and positron emission tomography to plan neurosurgery and subsequent treatments and analyze molecular alterations. It is noteworthy that molecular alterations could represent important prognostic factors and specific targets for precision medicine trials in these neoplasms. In the last few years, many translational and clinical studies have been performed, and new treatments with radiotherapy, new neurosurgical approaches, targeted therapy, immunotherapy, and combination treatments are ongoing. This Special Issue will cover all aspects of gliomas, including original research on advanced imaging, molecular characteristics, current and experimental treatment options, supportive care, neurocognitive functions, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Guest Editors

Dr. Giuseppe Lombardi

Department of Oncology, Veneto Institute of Oncology-IRCCS, Padua, Italy

Dr. Silvio Sarubbo

Department of Neurosurgery, "Santa Chiara" Hospital, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy

Deadline for manuscript submissions

closed (1 May 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/118981

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

